Adult Onset Still Disease Market is Expected to Expand at a Healthy Growth Rate During the Forecast Period (2022-2032), States DelveInsight | Key Companies – AB2 Bio Ltd., Cerecor, Roche, Swedish Orphan Biovitrum

Las Vegas (Nevada), United States //— DelveInsight’s “Adult Onset Still Disease Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Adult Onset Still Disease market size, share, and trends in the seven major markets (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan).

The Adult Onset Still Disease market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Adult Onset Still Disease: An Overview

Adult-onset Still’s disease (AOSD) is a rare inflammatory disorder that affects the entire body (systemic disease). The cause of the disorder is unknown (idiopathic). It has similar symptoms to systemic-onset juvenile idiopathic arthritis – fever, rash, and joint pain. The specific symptoms and frequency of episodes vary from one person to another, and the progression of the disorder is difficult to predict. In some individuals, the disorder appears suddenly, disappears almost as quickly and may not return. In other people, adult-onset Still’s disease is a chronic, potentially disabling condition.

Many different therapies have been tried for individuals with adult-onset Still’s disease. No one treatment has proven consistently effective in all cases. A variety of different drugs taken alone or in combination may be used to treat affected individuals.

Nonsteroidal anti-inflammatory drugs (NSAIDs) are often used to treat symptoms of inflammation. Fever, joint pain and bone pain have responded to treatment with these drugs. Other painkillers (analgesics) such as Tylenol (acetaminophen) may also be used.

In 2020, the U.S. Food and Drug Administration (FDA) approved Ilaris (canakinumab) to treat patients with active Still’s disease, including adult onset Still’s disease.

Adult Onset Still Disease Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Adult Onset Still Disease market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Adult Onset Still Disease market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Adult Onset Still Disease Epidemiology Assessment

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.

Learn More About the Evolving Epidemiology Trends @ Adult Onset Still Disease Epidemiology Analysis

Adult Onset Still Disease Drugs Uptake and Pipeline Development Activities

The drugs’ uptake section focuses on the rate of uptake of the potential drugs recently launched in the Adult Onset Still Disease market or expected to get launched during the study period. The analysis covers the Adult Onset Still Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Adult Onset Still Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Explore More About the Pipeline Development Activities @ Adult Onset Still Disease Therapeutics Pipeline Assessment

Adult Onset Still Disease Therapeutics Analysis

Several major pharma and biotech companies are developing therapies for Adult-Onset Still Disease. Currently, AB2 Bio Ltd. is leading the therapeutics market with its Adult-Onset Still Disease drug candidates in the mid to advanced stage of clinical development.

Some of the Leading Companies in the Adult Onset Still Disease Therapeutics Market Include:
– AB2 Bio Ltd.
– Cerecor
– Roche
– Swedish Orphan Biovitrum
And many others

Adult Onset Still Disease Therapies Covered in the Report Include:
– Tadekinig alfa: AB2 Bio Ltd.
– CERC-007: Cerecor
– Tocilizumab (TCZ) – Roche
– Anakinra – Swedish Orphan Biovitrum
And many more

Get a more detailed analysis @ Adult Onset Still Disease Emerging Therapies and Key Companies

Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Adult Onset Still Disease Competitive Intelligence Analysis
4. Adult Onset Still Disease Market Overview at a Glance
5. Disease Background and Overview
6. Adult Onset Still Disease Patient Journey
7. Adult Onset Still Disease Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Adult Onset Still Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Adult Onset Still Disease Unmet Needs
10. Key Endpoints of Adult Onset Still Disease Treatment
11. Adult Onset Still Disease Marketed Products
12. Adult Onset Still Disease Emerging Drugs and Latest Therapeutic Advances
13. Adult Onset Still Disease Seven Major Market Analysis
14. Attribute Analysis
15. Adult Onset Still Disease Market Outlook (In US, EU5, and Japan)
16. Adult Onset Still Disease Access and Reimbursement Overview
17. KOL Views on the Adult Onset Still Disease Market
18. Adult Onset Still Disease Market Drivers
19. Adult Onset Still Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Learn how the Adult Onset Still Disease market will evolve by 2032 @ Adult Onset Still Disease Market Outlook 2032

Contact Info:
Shruti Thakur
Manager (Marketing and Branding)
Email: info@delveinsight.com

Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic healthcare market today @ Healthcare Partner Identification Solutions

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.